This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
As an oral treatment intentionally designed for advanced use, VELSIPITY® helped calm the chaos of uncontrolled UC across multiple endpoints1–3
Significant and sustained clinical remission* vs placebo in ELEVATE UC 52 and ELEVATE UC 12, with 100% of patients who achieved clinical remission in ELEVATE UC 52 being steroid free1†
Symptomatic response as early as day 2 vs placebo in a pooled analysis of patients in ELEVATE UC 52 and ELEVATE UC 122
Endoscopic improvement‡ with VELSIPITY vs placebo in ELEVATE UC 52 and ELEVATE UC 12, further demonstrating the effectiveness of treatment1
Clinical and symptomatic remission were achieved in patients with isolated proctitis in both ELEVATE UC 52 and ELEVATE UC 12 vs placebo3
Read about the trial design of VELSIPITY®.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References:
Legal Category S1A
Further information available on request
PP-V1A-IRL-0024 Date of preparation February 2025
Adverse events should be reported.
If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie
Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.Registered in the Republic of Ireland No. 127002. Directors: M. Adamson (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.
Copyright © 2025 Pfizer Limited. All rights reserved.
The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.
I confirm that I am a healthcare professional* resident in the Republic of Ireland.
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.
*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses
Terms of use
PP-UNP-IRL-0901. July 2025